<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxandrolone (United States: FDA approval withdrawn): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxandrolone (United States: FDA approval withdrawn): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxandrolone (United States: FDA approval withdrawn): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10181" href="/d/html/10181.html" rel="external">see "Oxandrolone (United States: FDA approval withdrawn): Drug information"</a> and <a class="drug drug_patient" data-topicid="11856" href="/d/html/11856.html" rel="external">see "Oxandrolone (United States: FDA approval withdrawn): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block spa drugH1Div" id="F58345403"><span class="drugH1">Special Alerts</span>
<div class="collapsible">
<span class="collapsible-title">FDA Withdrawal of Oxandrolone Approval</span>
<span class="collapsible-date">June 2023</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;">Effective June 28, 2023, the FDA has withdrawn approval of the new drug application for Oxandrin (oxandrolone) held by Gemini Laboratories and the abbreviated new drug applications for oxandrolone from Upsher-Smith Laboratories, Par Pharmaceutical, and Sandoz. Multiple safety warnings and precautions are associated with the use of oxandrolone, including peliosis hepatis, sometimes associated with liver failure and intra-abdominal hemorrhage; liver cell tumors, sometimes fatal; and blood lipid changes that are known to be associated with increased risk of atherosclerosis. Additional warnings include the risks associated with cholestatic hepatitis, hypercalcemia in patients with breast cancer, and increased risk for the development of prostatic hypertrophy and prostatic carcinoma in older patients. Based on the available data, the FDA concluded that oxandrolone should be removed from the market. Distribution into interstate commerce without an approved application is illegal and subject to regulatory action.</p>
<p style="text-indent:0em;">Further information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2023%2F06%2F28%2F2023-13733%2Fgemini-laboratories-llc-et-al-withdrawal-of-approval-of-one-new-drug-application-for-oxandrin&amp;token=xLcwGyTsdrYnOtn4KiiSOXFefLPl5iRi8PLKYNxXatfRshX%2FsrVygjZhzhgOjjEiNRL%2BMPdlMz2Z%2B38dOo5RNOLuHj6uuMaSnDucBj2Ue0OMoqGP3%2BR9F8mymDl%2FIRXPS3sxUAev7iqLZXNjy0Ojbgih4OGpRj5qDBBrGvEVI6w%3D&amp;TOPIC_ID=94655" target="_blank">https://www.federalregister.gov/documents/2023/06/28/2023-13733/gemini-laboratories-llc-et-al-withdrawal-of-approval-of-one-new-drug-application-for-oxandrin</a>.</p></div>
</div>
</div>
<div class="block black-box-warn drugH1Div" id="F5709184"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Peliosis hepatis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Peliosis hepatis, a condition in which liver and, sometimes, splenic tissue is replaced with blood-filled cysts, has occurred in patients receiving androgenic anabolic steroids. These cysts are sometimes present with minimal hepatic dysfunction and have been associated with liver failure. Often, they are not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops. Withdrawal of drug usually results in complete disappearance of lesions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Liver cell tumors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Most often these tumors are benign and androgen-dependent, but fatal malignant tumors have occurred. Withdrawal of drug often results in regression or cessation of tumor progression. However, hepatic tumors associated with androgens or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening, intra-abdominal hemorrhage develops.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Blood lipid changes:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Blood lipid changes associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids. These changes include decreased high-density lipoprotein (HDL) and, sometimes, increased low-density lipoprotein (LDL). The changes may be very marked and could have a serious impact on the risk of atherosclerosis and coronary artery disease.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1028862"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Anabolic Steroid</span>;</li>
<li>
<span class="list-set-name">Androgen</span></li></ul></div>
<div class="block dop drugH1Div" id="F204334"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Effective June 28, 2023, the FDA has withdrawn approval of the new drug application for oxandrolone for all indications. Distribution into interstate commerce without an approved application is illegal and subject to regulatory action.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="63fec1d8-7a28-47e8-9b4e-08d59c8e11f6">Burn management, severe; to increase lean muscle mass and promote wound healing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Burn management, severe; to increase lean muscle mass and promote wound healing:</b> Limited data available: Children and Adolescents: Oral: 0.1 mg/kg/dose twice daily for up to 12 months has been shown to increase lean body mass, bone mineral density, and muscle strength; shortened length of ICU stay and improved donor site wound healing were also observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11303139','lexi-content-ref-17717439','lexi-content-ref-15300183','lexi-content-ref-22463890','lexi-content-ref-16135924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11303139','lexi-content-ref-17717439','lexi-content-ref-15300183','lexi-content-ref-22463890','lexi-content-ref-16135924'])">Ref</a></span>). Benefits have been shown to persist for up to 5 years post burn (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22463890','lexi-content-ref-16135924']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22463890','lexi-content-ref-16135924'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7471abe8-bd58-44ac-b865-e47b18736eb5">Constitutional delay of growth and puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constitutional delay of growth and puberty (CDGP) (males):</b> Limited data available: Children and Adolescents 9 to 16 years: Oral: 1.25 to 2.5 mg once daily in the evening; usual duration: 3 to 12 months although longer (~5 years) has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7979523','lexi-content-ref-2346341','lexi-content-ref-1863096','lexi-content-ref-8801102','lexi-content-ref-4004317','lexi-content-ref-3389864','lexi-content-ref-2213384']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7979523','lexi-content-ref-2346341','lexi-content-ref-1863096','lexi-content-ref-8801102','lexi-content-ref-4004317','lexi-content-ref-3389864','lexi-content-ref-2213384'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c5e6cbb8-2619-46d9-9bba-b4c59c48b5ce">Turner syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Turner syndrome (females):</b> Limited data available: Children and Adolescents ≥8 years: Oral: Reported range: 0.03 to 0.06 mg/kg/day at bedtime in combination with growth hormone and/or estrogen; maximum single dose: 2.5 mg/dose; due to risks of dose-related virilization, doses ≥0.05 mg/kg/day should generally be avoided. Typically, therapy initiated at 8 to 9 years of age and continued until goal height attained or further growth is unlikely (eg, bone age ≥14 years and growth velocity &lt;2 cm/year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9177976','lexi-content-ref-17047017','lexi-content-ref-23076845','lexi-content-ref-21493672','lexi-content-ref-7545577','lexi-content-ref-20061421','lexi-content-ref-8636281']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9177976','lexi-content-ref-17047017','lexi-content-ref-23076845','lexi-content-ref-21493672','lexi-content-ref-7545577','lexi-content-ref-20061421','lexi-content-ref-8636281'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4a5b890f-4159-4a8a-ae24-cb0f52c77309">Weight gain, adjunct</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight gain, adjunct:</b> Children and Adolescents: Oral: Total daily dose: ≤0.1 mg/kg; may be repeated intermittently as needed; in adult patients, the daily dose is divided 2 to 4 times daily; typical duration of therapy: 2 to 4 weeks</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51151036"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling. Caution is recommended because of the propensity of oxandrolone to cause edema and water retention.</p></div>
<div class="block dohp drugH1Div" id="F51151037"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F204323"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10181" href="/d/html/10181.html" rel="external">see "Oxandrolone (United States: FDA approval withdrawn): Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Effective June 28, 2023, the FDA has withdrawn approval of the new drug application for oxandrolone for all indications. Distribution into interstate commerce without an approved application is illegal and subject to regulatory action.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="79514b59-1174-4fcb-ac68-983885af5284">Burns, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Burns, moderate to severe (adjunctive agent) (off-label use):</b>
<b>Oral:</b> 10 mg every 12 hours; generally start within the first ~7 days following injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26454425','lexi-content-ref-31504621','lexi-content-ref-16566555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26454425','lexi-content-ref-31504621','lexi-content-ref-16566555'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc13bb71-a539-4191-9c08-f429cad8dcc2">Osteoporosis-associated bone pain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteoporosis-associated bone pain (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Available data to support use in this condition are limited. Current guidelines for the treatment of osteoporosis do not include recommendations for the use of oxandrolone for this purpose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30907953','lexi-content-ref-25182228','lexi-content-ref-35378630']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30907953','lexi-content-ref-25182228','lexi-content-ref-35378630'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.5 to 20 mg/day in 2 to 4 divided doses based on individual response; a course of therapy of 2 to 4 weeks is usually adequate. May repeat intermittently as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81fdea5f-b9ec-4b6b-8f4c-51bf2eac2b3b">Protein catabolism, corticosteroid-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Protein catabolism, corticosteroid-induced (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Available data to support use for this purpose are limited.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.5 to 20 mg/day in 2 to 4 divided doses based on individual response; a course of therapy of 2 to 4 weeks is usually adequate. May repeat intermittently as needed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a5318605-54e0-43c0-b28a-7e670560b692">Weight gain</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight gain (adjunctive agent</b>
<b>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Studies of oxandrolone in patients with weight loss associated with HIV/AIDS and chronic obstructive pulmonary disease have not consistently shown improvement in functional status or quality of life and many did not include females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16540931','lexi-content-ref-20164318','lexi-content-ref-36148458']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16540931','lexi-content-ref-20164318','lexi-content-ref-36148458'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 2.5 to 20 mg/day in 2 to 4 divided doses based on individual response; a course of therapy of 2 to 4 weeks is usually adequate. May repeat intermittently as needed.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992036"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution due to propensity to cause edema.</p></div>
<div class="block doha drugH1Div" id="F50989332"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Preexisting impairment: </i>There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during therapy</i>: Discontinue use if abnormal LFTs or cholestatic hepatitis with jaundice occurs; changes in LFTs and drug-induced jaundice are reversible upon discontinuation.</p></div>
<div class="block adr drugH1Div" id="F204306"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Deepening of the voice (females), depression, excitement, habituation, insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (females and prepubertal males), androgenetic alopecia (females)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Changes in libido, decreased glucose tolerance, decreased HDL cholesterol, electrolyte disturbance, gynecomastia, hirsutism (females), increased LDL cholesterol, inhibition of gonadotropin secretion, menstrual disease (females)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Clitoromegaly (females), epididymitis (postpubertal males), erectile dysfunction (prepubertal males; increased or persistent erections), impotence (postpubertal males), inhibition of testicular function (postpubertal males), irritable bladder (postpubertal males), oligospermia (postpubertal males), phallic enlargement (prepubertal males), priapism (chronic; postpubertal males), testicular atrophy (postpubertal males)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Clotting factors suppression, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatocellular neoplasm, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, peliosis hepatitis (long-term therapy)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, premature epiphyseal closure (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased creatinine clearance</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hepatic necrosis, hepatotoxicity (idiosyncratic; Chalasani 2014)</p></div>
<div class="block coi drugH1Div" id="F204316"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Nephrosis; breast cancer in females with hypercalcemia; known or suspected prostate or breast cancer in males; hypercalcemia; pregnancy</p></div>
<div class="block war drugH1Div" id="F204303"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood lipid changes: Use caution in patients at risk for, or with a history of cardiovascular disease; monitor lipid profile and adjust therapy as indicated. Lipid changes are usually reversible upon discontinuation of therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gynecomastia: May cause gynecomastia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oligospermia: May suppress spermatogenesis; oligospermia may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polycythemia: Increased hemoglobin and hematocrit may occur with high doses of anabolic steroids.</p>
<p style="text-indent:-2em;margin-left:4em;">• Priapism: Priapism or excessive sexual stimulation may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: Use with caution in females with breast cancer; may cause hypercalcemia by stimulating osteolysis; use is contraindicated in females with breast cancer and hypercalcemia. Discontinue use if hypercalcemia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in patients with diabetes.</p>
<p style="text-indent:-2em;margin-left:4em;">• COPD: Use with caution in patients with COPD.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, hepatic impairment, renal impairment); may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults; older males may be at greater risk for prostatic hyperplasia and prostate cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May accelerate bone maturation without producing compensatory gain in linear growth in children; effect may continue for 6 months after the drug is stopped; in prepubertal children perform radiographic examination of the left hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.</p>
<p style="text-indent:-2em;margin-left:4em;">• Females: May cause mild virilization in females. Discontinue with evidence of mild virilization in female patients; early discontinuation may prevent irreversible virilization.</p></div>
<div class="block prod-avail drugH1Div" id="F58435940"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Effective June 28, 2023, the FDA has withdrawn approval of the new drug application for oxandrolone for all indications. Distribution into interstate commerce without an approved application is illegal and subject to regulatory action. Further information is available at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2023%2F06%2F28%2F2023-13733%2Fgemini-laboratories-llc-et-al-withdrawal-of-approval-of-one-new-drug-application-for-oxandrin&amp;token=xLcwGyTsdrYnOtn4KiiSOXFefLPl5iRi8PLKYNxXatfRshX%2FsrVygjZhzhgOjjEiNRL%2BMPdlMz2Z%2B38dOo5RNOLuHj6uuMaSnDucBj2Ue0OMoqGP3%2BR9F8mymDl%2FIRXPS3sxUAev7iqLZXNjy0Ojbgih4OGpRj5qDBBrGvEVI6w%3D&amp;TOPIC_ID=94655" target="_blank">https://www.federalregister.gov/documents/2023/06/28/2023-13733/gemini-laboratories-llc-et-al-withdrawal-of-approval-of-one-new-drug-application-for-oxandrin</a>.</p></div>
<div class="block foc drugH1Div" id="F204313"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg [DSC], 10 mg [DSC]</p></div>
<div class="block geq drugH1Div" id="F204299"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F204317"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Oxandrolone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $5.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $18.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block exp drugH1Div" id="F12737086"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 1 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet® and Ora-Plus®, or a 1:1 mixture of Ora-Sweet® SF and Ora-Plus®.  Crush twenty-four 2.5 mg tablets in a mortar to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to <b>almost </b>60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Thoroughly mix the suspension by shaking. Label “shake well” and “protect from light”. Stable for 90 days at room temperature (Johnson, 2011).</p>
<div class="reference">Johnson CE, Cober MP, Hawkins KA, et al, “Stability of Extemporaneously Prepared Oxandrolone Oral Suspensions,” <i>Am J Health-Syst Pharm</i>, 2011, 68(6):519-21.<span class="pubmed-id">21378300</span></div>
</div>
<div class="block csi drugH1Div" id="F204339"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-III</p></div>
<div class="block admp drugH1Div" id="F52617895"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: For patients unable to swallow tablets, an oral suspension may be extemporaneously prepared (see Extemporaneous Preparations for additional information). In adults (severe burn), oxandrolone tablets were dissolved in ethanol and administered through enteral feeding tube (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16566555']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16566555'])">Ref</a></span>); pediatric experience has not been reported.</p></div>
<div class="block adm drugH1Div" id="F52080871"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Enteral feeding tube (off label): In severe burn patients unable to tolerate oral administration, oxandrolone may be extemporaneously prepared and administered via enteral feeding tube (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21378300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21378300'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F16122838"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53568142"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Effective June 28, 2023, the FDA has withdrawn approval of the new drug application for oxandrolone for all indications. Distribution into interstate commerce without an approved application is illegal and subject to regulatory action.</p>
<p style="text-indent:-2em;margin-left:2em;">Adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who, without definite pathophysiologic reasons, fail to gain or to maintain normal weight; to offset protein catabolism with prolonged corticosteroid administration and for the relief of bone pain associated with osteoporosis (All indications: FDA approved in children and adults); has also been used in the management of Turner syndrome in girls, constitutional delay of growth and puberty (CDGP), and for postoperative burn management to increase lean muscle mass and promote wound healing.</p></div>
<div class="block mst drugH1Div" id="F56412976"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299799"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F204307"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Androgens may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).  Management: Consider avoiding concomitant use of androgens and cyclosporine. If concomitant use is unavoidable, monitor serum cyclosporine concentrations and for signs and symptoms of hepatotoxicity. Cyclosporine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypertension-Associated Agents: May enhance the hypertensive effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F204318"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in pregnant women; masculinization of the fetus has been reported.</p></div>
<div class="block mopp drugH1Div" id="F53568118"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver function tests, lipid profile, hemoglobin/hematocrit; INR/PT in patients on anticoagulant therapy </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Children: Radiographs of left wrist every 6 months to assess bone maturation </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Females: Signs of virilization (deepening voice, hirsutism, acne, clitoromegaly); urine and serum calcium in women with breast cancer </p></div>
<div class="block pha drugH1Div" id="F204302"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Synthetic testosterone derivative with similar androgenic and anabolic actions</p></div>
<div class="block phk drugH1Div" id="F854656"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Well absorbed (Orr 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95% (Orr 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 10 to 13 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak serum concentration: ~1 hour (Orr 2004)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (28% as unchanged drug) (Orr 2004)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539909"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lonavar | Oxandrin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lonavar</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lonavar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Lonavar | Vasorome</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Kicker | Lonavar</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Xtendrol</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Oxandrolone spa</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Oxandrin</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Oxandroland</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lonavar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Lonavar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-7979523">
<a name="7979523"></a>Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R. Oral treatment for constitutional delay of growth and puberty in boys: a randomized trial of an anabolic steroid or testosterone undecanoate. <i>Arch Dis Child</i>. 1994;71(4):315-317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/7979523/pubmed" id="7979523" target="_blank">7979523</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AGS.1">
<a name="AGS.1"></a>American Geriatrics Society. Choosing wisely: an initiative of the ABIM Foundation. Ten things clinicians and patients should question. https://www.choosingwisely.org/clinician-lists/american-geriatrics-society-prescription-appetite-stimulants-to-treat-anorexia-cachexia-in-elderly/?highlight=weight%20gain. Updated April 23, 2015. Accessed March 16, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9177976">
<a name="9177976"></a>Bareille P, Massarano AA, Stanhope R. Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. <i>Eur J Pediatr</i>. 1997;156:358-362.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/9177976/pubmed" id="9177976" target="_blank">9177976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17047017">
<a name="17047017"></a>Bondy CA, Turner Syndrome Consensus Study Group. Care of girls and women with Turner Syndrome: a guideline of the Turner Syndrome Study Group.<i> J Clin Endocrinol Metab</i>. 2007;92(1):10-25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/17047017/pubmed" id="17047017" target="_blank">17047017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2346341">
<a name="2346341"></a>Buyukgebiz A, Hindmarsh PC, Brook CGD. Treatment of constitutional delay of growth and puberty with oxandrolone compared with growth hormone. <i>Arch Dis Child</i>. 1990;65(4):448-449.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/2346341/pubmed" id="2346341" target="_blank">2346341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25182228">
<a name="25182228"></a>Cosman F, de Beur SJ, LeBoff MS, et al; National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi:10.1007/s00198-014-2794-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/25182228/pubmed" id="25182228" target="_blank">25182228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Demling.1">
<a name="Demling.1"></a>Demling R, DeSanti L. The beneficial effects of the anabolic steroid oxandrolone in the geriatric burn population. <i>Wounds</i>. 2003;15(2):54-58.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30907953">
<a name="30907953"></a>Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1595-1622. doi:10.1210/jc.2019-00221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/30907953/pubmed" id="30907953" target="_blank">30907953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23076845">
<a name="23076845"></a>Freriks K, Sas TCJ, Traas MAF, et al. Long-term effects of previous oxandrolone treatment in adult women with Turner syndrome. <i>Eur J Endocrinol</i>. 2012;168(1):91-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/23076845/pubmed" id="23076845" target="_blank">23076845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21493672">
<a name="21493672"></a>Gault EJ, Perry R, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomized, double blind, placebo controlled trial. <i>BMJ</i>. 2011;342:d1980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/21493672/pubmed" id="21493672" target="_blank">21493672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35378630">
<a name="35378630"></a>Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. <i>Arch Osteoporos</i>. 2022;17(1):58. doi:10.1007/s11657-022-01061-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/35378630/pubmed" id="35378630" target="_blank">35378630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16540931">
<a name="16540931"></a>Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. <i>J Acquir Immune Defic Syndr</i>. 2006;41(3):304-314. doi:10.1097/01.qai.0000197546.56131.40<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/16540931/pubmed" id="16540931" target="_blank">16540931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20164318">
<a name="20164318"></a>Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. <i>Am J Clin Nutr</i>. 2010;91(4):1143S-1147S. doi:10.3945/ajcn.2010.28608E<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/20164318/pubmed" id="20164318" target="_blank">20164318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11303139">
<a name="11303139"></a>Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. <i>Ann Surg</i>. 2001;233(4):556-564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/11303139/pubmed" id="11303139" target="_blank">11303139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7545577">
<a name="7545577"></a>Haeusler G, Frisch H, Schmitt K, et.al. Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. <i>Eur J Pediatr</i>. 1995;154(6):437-444.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/7545577/pubmed" id="7545577" target="_blank">7545577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17717439">
<a name="17717439"></a>Jeschke MG, Finnerty CC, Suman OE, Kulp G, Mlcak RP, Herndon DN. The effect of oxandrolone on the endocrinologic, inflammatory, and hypermetabolic responses during the acute phase postburn. <i>Ann Surg</i>. 2007;246(3):351-360.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/17717439/pubmed" id="17717439" target="_blank">17717439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21378300">
<a name="21378300"></a>Johnson CE, Cober MP, Hawkins KA, Julian JD. Stability of extemporaneously prepared oxandrolone oral suspensions. <i>Am J Health Syst Pharm</i>. 2011;68(6):519-521. doi:10.2146/ajhp100225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/21378300/pubmed" id="21378300" target="_blank">21378300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26454425">
<a name="26454425"></a>Li H, Guo Y, Yang Z, Roy M, Guo Q. The efficacy and safety of oxandrolone treatment for patients with severe burns: a systematic review and meta-analysis. <i>Burns</i>. 2016;42(4):717-727. doi: 10.1016/j.burns.2015.08.023.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/26454425/pubmed" id="26454425" target="_blank">26454425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36148458">
<a name="36148458"></a>Liu Y, Huang C, Du J, et al. Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>Front Med (Lausanne)</i>. 2022;9:915159. doi:10.3389/fmed.2022.915159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/36148458/pubmed" id="36148458" target="_blank">36148458</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20061421">
<a name="20061421"></a>Menke LA, Sas TCJ, de Muinck Keizer-Schrama SMPF, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner Syndrome. <i>J Clin Endocrinol Metab</i>. 2010;95(3):1151-1160.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/20061421/pubmed" id="20061421" target="_blank">20061421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15300183">
<a name="15300183"></a>Murphy KD, Thomas S, Mlcak RP, Chinkes DL, Klein GL, Herndon DN. Effects of long-term oxandrolone administration in severely burned children. <i> Surgery</i>. 2004;136(2):219-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/15300183/pubmed" id="15300183" target="_blank">15300183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8636281">
<a name="8636281"></a>Nilsson KA, Albertsson-Wikland K, Alm J, et al. Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone. <i>J Clin Endocrinol Metab</i>. 1996;81(2):635-640.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/8636281/pubmed" id="8636281" target="_blank">8636281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15025546">
<a name="15025546"></a>Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders. Review of efficacy and safety. <i>Drugs</i>. 2004;64(7):725-750.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/15025546/pubmed" id="15025546" target="_blank">15025546</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Oxandrolone [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1863096">
<a name="1863096"></a>Papadimitriou A, Wacharasindhu S, Pearl K, Preece MA, Stanhope R. Treatment of constitutional growth delay in prepubertal boys with a prolonged course of low dose oxandrolone. <i>Arch Dis Child</i>. 1991;66(7):841-843.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/1863096/pubmed" id="1863096" target="_blank">1863096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22463890">
<a name="22463890"></a>Porro LJ, Herndon DN, Rodriguez NA, et al. Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. <i>J Am Coll Surg</i>. 2012;214(4):489-504.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/22463890/pubmed" id="22463890" target="_blank">22463890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16135924">
<a name="16135924"></a>Przkora R, Jeschke MG, Barrow RE, et al. Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment. <i>Ann Surg</i>. 2005;242(3):384-389.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/16135924/pubmed" id="16135924" target="_blank">16135924</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31504621">
<a name="31504621"></a>Ring J, Heinelt M, Sharma S, Letourneau S, Jeschke MG. Oxandrolone in the treatment of burn injuries: a systematic review and meta-analysis. <i>J Burn Care Res</i>. 2020;41(1):190-199. doi:10.1093/jbcr/irz155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/31504621/pubmed" id="31504621" target="_blank">31504621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8801102">
<a name="8801102"></a>Schroor EJ, van Weissenbruch MM, Knibbe P, Delemarre-van de Waal HA. The effect of prolonged administration of an anabolic steroid (oxandrolone) on growth in boys with constitutionally delayed growth and puberty.<i> Eur J Pediatr</i>. 1995;154(12):953-957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/8801102/pubmed" id="8801102" target="_blank">8801102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4004317">
<a name="4004317"></a>Stanhope R, Brook CGD. Oxandrolone in low dose for constitutional delay of growth and puberty in boys. <i>Arch Dis Child</i>. 1985;60(4):379-381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/4004317/pubmed" id="4004317" target="_blank">4004317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3389864">
<a name="3389864"></a>Stanhope R, Buchanan CR, Fenn GC, Preece MA. Double blind placebo controlled trial of low dose oxandrolone in the treatment of boys with constitutional delay of growth and puberty. <i>Arch Dis Child</i>. 1988;63(5):501-505.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/3389864/pubmed" id="3389864" target="_blank">3389864</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2213384">
<a name="2213384"></a>Tse WY, Buyukgebiz A, Hindmarsh PC, Stanhope R, Preece MA, Brook CG. Long-term outcome of oxandrolone treatment in boys with constitutional delay of growth and puberty. <i>J Pediatr</i>. 1990;117(4):588-591.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/2213384/pubmed" id="2213384" target="_blank">2213384</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16566555">
<a name="16566555"></a>Wolf SE, Edelman LS, Kemalyan N, et al. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. <i>J Burn Care Res</i>. 2006;27(2):131-139; discussion 140-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxandrolone-united-states-fda-approval-withdrawn-pediatric-drug-information/abstract-text/16566555/pubmed" id="16566555" target="_blank">16566555</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 94655 Version 103.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
